STAT+: Biogen’s tau-targeting Alzheimer’s drug posts mixed results in mid-stage study

Biogen's tau-targeting Alzheimer's drug diranersen showed mixed results in a mid-stage clinical trial, reducing tau levels and slowing cognitive decline, but failed to achieve its primary efficacy goal. The study investigated three escalating dosing regimens, with the lowest dose showing the best results. Biogen reported that tau reductions correlated to a slowing of cognitive decline.